Zynex, Inc.
1.3200+0.00 (+0%)
Oct 29, 4:00:00 PM EDT · NasdaqGS · ZYXI · USD
Key Stats
Market Cap
39.99MP/E (TTM)
-Basic EPS (TTM)
-0.93Dividend Yield
0%Recent Filings
8-K
Zynex appoints Wise to board
Zynex bolstered its board on October 7, 2025, by electing Bret W. Wise as a director and Audit Committee Chair, leveraging his deep medical device expertise from leading Dentsply International and Sirona. This move, amid CEO transition, aims to sharpen financial oversight and compliance. Wise's addition strengthens governance. Yet, Chief Commercial Officer Anna Lucsok resigned effective October 10, 2025, potentially disrupting sales momentum.
8-K
Zynex shifts NiCO strategy
Zynex pivoted strategy for its Zynex Monitoring Solutions unit on October 1, 2025, seeking a partner to commercialize the NiCO CO-Oximeter after FDA 510(k) submission, axing most ZMS staff for cost savings. This triggers $0.1 million in severance and up to $31.0 million in impairments, hitting Q3 for assets and Q4 for cash. No partner yet. Success hinges on finding a taker.
8-K
Zynex appoints key executives
Zynex appointed Vikram Bajaj as CFO and John Bibb as Chief Legal Officer on August 18, 2025, succeeding Dan Moorhead who departs August 29. Both executives, with deep med-tech experience from Vyaire and KCI, receive $450,000 base salaries and $5 million in inducement equity each. The board also elected CEO Steven Dyson as a director without extra pay. New team targets improved performance amid reimbursement risks.
8-K
Zynex Q2 revenue plunges
Zynex reported Q2 2025 net revenue of $22.3 million, down sharply from $49.9 million a year ago, hit by Tricare payment suspension and sales force restructuring. Gross profit fell to $15.2 million at 68% of revenue, while sales and marketing expenses dropped 45% to $12.8 million; net loss hit $20.0 million, including a $10.3 million deferred tax allowance. Leadership shifts with Steven Dyson's CEO appointment and FDA submission for NiCO oximeter aim to refocus strategy, but Q3 guidance is suspended amid executive changes. Cost cuts promise $40 million in annual savings.
10-Q
Q2 FY2025 results
Zynex's Q2 revenue plunged 55% y/y to $22.3M, with supplies dropping 67% due to Tricare's ongoing payment suspension over billing allegations, while devices fell 31% amid a 20% order decline from sales force cuts. Operating loss widened to $10.3M from $2.2M profit, driven by higher gross margins at 68% yet ballooning sales and admin costs as percentages of revenue; net loss hit $20.0M, or $(0.66) diluted EPS on 30.3M shares, with the tax hit from a $6.8M valuation allowance pushing the gap beyond operations. Cash drained to $17.5M after $16.7M operating outflow and $4.9M treasury buyback, leaving liquidity tight against $60M notes due May 2026. Workforce trims saved $40M annually. Tricare woes linger.
CVRX
CVRx, Inc.
10.81+0.09
DYNT
Dynatronics Corp.
0.05+0.00
EMED
Electromedical Technologies, In
0.00+0.00
MASI
Masimo Corporation
142.91-3.50
NAOV
NanoVibronix, Inc.
5.57-0.32
NPCE
Neuropace, Inc.
10.13-0.49
NUWE
Nuwellis, Inc.
3.05-0.05
NXGL
NexGel, Inc
2.45-0.11
STIM
Neuronetics, Inc.
2.90-0.20
VYCO
Vycor Medical, Inc.
0.15+0.00